title: [Infective endocarditis].
abstract: Colonization of native cardiac valves or polymer implants, e.g. valves, conduits, rings, electrode leads and polymer-associated endocarditis (PIE), by microorganisms, primarily gram-positive bacteria (infective endocarditis), constitutes a severe, prognostically unfavorable disease. Fever and in the majority of cases development of a valve regurgitant murmur are clinical landmark findings. The white blood cell count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are regularly elevated. With a normal CRP level, infective endocarditis is extremely unlikely. Irrespective of body temperature, at least three blood cultures (aerobic and anaerobic) should be taken and if initiation of antimicrobial therapy is urgent, 1 h apart before therapy is initiated. Identification of the pathogen to the species level and testing antimicrobial susceptibility to antibiotics by a quantitative hemodilution test, not with agar diffusion tests, are obligatory. A minimum inhibitory concentration should be administered for antibiotics and usual combinations of antibiotics with an expected synergistic potential. Streptococci, staphylococci and enterococci are the most frequent causative organisms. Immediate initiation of transthoracic echocardiography (TTE) is mandatory followed by transesophageal echocardiography if imaging quality is poor, involvement of intracardiac implants is possible or TTE is insufficient to establish the diagnosis. An insufficiently long antimicrobial therapy promotes recurrent infections, thus a 4-week treatment is standard, while in special cases (e.g. PIE) treatment for 6 weeks should be the rule. If typical complications of infective endocarditis, such as uncontrolled local infection, systemic thromboembolism, central nervous involvement, development of a severe valve incompetence or mitral kissing vegetation in primary aortic valve endocarditis occur, urgent surgical intervention should be considered. If cardiac implants are involved, early surgical removal followed by a 6-week antimicrobial treatment is the rule. Adequate and timely diagnosis and treatment are the key to improve the overall prognosis.
authors.affiliation: Klinik für Kardiologie, Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Deutschland, akleemeyer@hdz-nrw.de.
authors.forename: D
authors.initials: D
authors.lastname: Horstkotte
authors.forename: C
authors.initials: C
authors.lastname: Piper
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D013504:Cardiovascular Surgical Procedures / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D004452:Echocardiography / Q000379:methods; D004697:Endocarditis, Bacterial / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy*; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents
references.citation: FEMS Immunol Med Microbiol. 2006 Jun;47(1):1-13
references.pmid: 16706783
references.citation: J Immunol Methods. 1989 Oct 24;123(2):217-25
references.pmid: 2509565
references.citation: Clin Infect Dis. 2000 Apr;30(4):633-8
references.pmid: 10770721
references.citation: Arch Intern Med. 2009 Mar 9;169(5):463-73
references.pmid: 19273776
references.citation: Am J Med. 1992 Apr;92(4):391-5
references.pmid: 1307218
references.citation: Am J Med. 1994 Mar;96(3):200-9
references.pmid: 8154507
references.citation: Am Heart J. 2007 Nov;154(5):923-8
references.pmid: 17967599
references.citation: Circulation. 2005 Jun 14;111(23):e394-434
references.pmid: 15956145
references.citation: Eur Heart J. 2002 Jan;23 (1):79-86
references.pmid: 11741365
references.citation: Eur Heart J. 2014 May;35(18):1195-204
references.pmid: 23964033
references.citation: Am J Med. 1996 Jun;100(6):629-33
references.pmid: 8678083
references.citation: Eur Heart J. 2010 May;31(9):1105-13
references.pmid: 20093256
references.citation: Eur Heart J. 2009 Oct;30(19):2369-413
references.pmid: 19713420
references.citation: Eur Heart J. 2004 Feb;25(3):267-76
references.pmid: 14972429
references.citation: J Heart Valve Dis. 2001 Nov;10(6):703-11
references.pmid: 11767174
references.citation: J Clin Microbiol. 2005 Oct;43(10):5238-42
references.pmid: 16207989
references.citation: Am J Cardiol. 2006 Nov 1;98 (9):1261-8
references.pmid: 17056343
references.citation: Am J Cardiol. 2006 Nov 1;98(9):1254-60
references.pmid: 17056342
references.citation: Z Kardiol. 1986;75 Suppl 2:168-82
references.pmid: 3524043
references.citation: Heart. 2004 Jun;90(6):614-7
references.pmid: 15145856
references.citation: Heart. 2003 Mar;89(3):258-62
references.pmid: 12591823
references.citation: Circulation. 2005 Mar 22;111(11):1415-21
references.pmid: 15753218
references.citation: PLoS One. 2013 Dec 09;8(12):e82665
references.pmid: 24349331
references.citation: Internist (Berl). 2008 Jan;49(1):34-42
references.pmid: 18231761
references.citation: Heart. 2004 Sep;90(9):1020-4
references.pmid: 15310690
references.citation: Eur J Clin Microbiol Infect Dis. 2004 May;23(5):353-65
references.pmid: 15112074
references.citation: J Heart Valve Dis. 1998 May;7(3):313-5
references.pmid: 9651845
references.citation: J Am Coll Cardiol. 2002 Apr 3;39(7):1204-11
references.pmid: 11923047